PB2103: CAN WE ACCURATELY PREDICT SURVIVAL IN DIFFUSE LARGE B CELL LYMPHOMA IN THE RITUXIMAB ERA? RETROSPECTIVE COMPARISON OF IPI, AAIPI, R-IPI AND NCCN-IPI
Main Authors: | P. Chorão, M. Henriques, P. Baptista, I. Carvalhais, A. L. Pinto, P. Silva, A. M. Carneiro, F. Ferreira, F. Trigo |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000851244.27592.9f |
Similar Items
-
External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival
by: Naree Warnnissorn, et al.
Published: (2022-12-01) -
IPI: uma abordagem constitucional
by: Guilherme Luis Muramatsu Pereira, et al.
Published: (2009-07-01) -
The history of the International Polar Years (IPYs) /
by: Barr, Susan
Published: (c201) -
PRINTsIPY DIAGNOSTIKI RANNEGO REVMATOIDNOGO ARTRITA
by: I B Belyaeva, et al.
Published: (2005-06-01) -
Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study
by: Dalle, S, et al.
Published: (2019)